Impact of patient background factors on the treatment efficacy of once-weekly teriparatide
10.1016/j.afos.2019.04.001
- Author:
Fumitoshi OMURA
1
,
2
Author Information
1. Koenji Orthopedics Clinic, Tokyo, Japan. oomura-f@rg
2. so-net.ne.jp.
- Publication Type:Original Article
- Keywords:
Teriparatide;
Osteoporosis;
Bone mineral density;
Visual analogue scale;
Bone metabolic markers
- MeSH:
Bone Density;
Femur;
Humans;
Neck;
Osteoporosis;
Reference Values;
Spine;
Teriparatide;
Treatment Outcome
- From:Osteoporosis and Sarcopenia
2019;5(2):51-56
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: The impact of patient background factors on changes in bone mineral density (BMD) and bone metabolic markers after treatment with once-weekly teriparatide (W-TPTD) has not been fully elucidated. To clarify the impact, I performed stratified analysis in addition to the efficacy and safety assessments to analyze treatment data with W-TPTD. METHODS: The primary endpoint of the efficacy was the rate of change of the lumbar spine BMD at 18 months after treatment. In the exploratory analysis, bone metabolic markers at baseline were used to divide the patients into 3 groups, by the first tertile and the second tertile. The rate of change in the lumbar spine/femoral neck BMD and bone metabolic markers in each group were analyzed by stratification. RESULTS: The rate of change in the lumbar spine BMD at 18 months was 9.0%, which represented a significant increase. The rate of change in the lumbar spine/femoral neck BMD in each group classified into tertiles by their baseline bone metabolic markers significantly increased, regardless of the type of bone metabolic markers and baseline value. For markers, all groups remained within the range of reference values at 18 months after treatment. CONCLUSIONS: I demonstrated that W-TPTD significantly increased the BMD of the lumbar spine and femur, regardless of baseline values of the bone metabolic markers. In addition, W-TPTD was able to normalize bone metabolic markers. I considered that W-TPTD would be useful, independent of bone metabolic markers in patients, as an agent to improve BMD, and be a useful option for the treatment of osteoporosis.
